Targeting AKT with the proapoptotic peptide, TAT-CTMP: A novel strategy for the treatment of human pancreatic adenocarcinoma

International Journal of Cancer

Volumn 125, Issue 4, 2009, Pages 942-951

  Simon Jr , Peter O ^a   McDunn, Jonathan E ^a   Kashiwagi, Hiroyuki ^a   Chang, Katherine ^a   Goedegebuure, Peter S ^a,b   Hotchkiss, Richard S ^a   Hawkins, William G ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

Author keywords

AKT; Apoptosis; CTMP; Pancreas cancer

Indexed keywords

CASPASE 3; CELL PENETRATING PEPTIDE; GEMCITABINE; PEPTIDE DERIVATIVE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; WORTMANNIN;

ADJUVANT THERAPY; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; DRUG TARGETING; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; PANCREAS ADENOCARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR VOLUME; TUMOR XENOGRAFT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CASPASES; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, NUDE; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION TOLERANCE; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67650079902     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24424     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics 2008. CA Cancer J Clin 2008;58:71-96.
2. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the national cancer database. J Am Coll Surg 1999;189:1-7.
3. Prochazkova J, Lichnovsky V, Kylarova D, Erdosova B, Vranka P. Involvement of p53 and Bcl-2 family proteins in regulating programmed cell death and proliferation in human embryogenesis. Gen Physiol Biophys 2004;23:209-29.
4. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205-19.
5. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene 2004;23:2950-66.
6. Bergman PJ, Harris D. Radioresistance, chemoresistance, and apoptosis resistance. The past, present, and future. Vet Clin North Am Small Anim Pract 1997;27:47-57.
7. Tan TT, Degenhardt K, Nelson DA, Beaudoin B, Nieves-Neira W, Bouillet P, Villunger A, Adams JM, White E. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005;7:227-38.
8. Decaudin D, Marzo I, Brenner C, Kroemer G. Mitochondria in chemotherapy-induced apoptosis: a prospective novel target of cancer therapy (review). Int J Oncol 1998;12:141-52.
9. Piro LD. Apoptosis. Bcl-2 antisense, and cancer therapy. Oncology 2004;18:5-10.
10. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985;228:1440-43.
11. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407: 770-76.
12. Zantl N, Weirich G, Zall H, Seiffert BM, Fischer SF, Kirschnek S, Hartmann C, Fritsch RM, Gillissen B, Daniel PT, Häcker G. Frequent loss of expression of the proapoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance. Oncogene 2007;26:7038-48.
13. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3′-kinsae-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 2002;1:989-97.
14. Xiong HQ. Molecular targeting therapy for pancreas cancer. Cancer Chemother Pharmacol 2004;54:S69-77.
15. Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Dong QG, Abbruzzese JL, Evans DB, Baker C, Chiao PJ. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res 2003; 9:346-54.
16. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-57.
17. Leach SD. Mouse models of pancreatic cancer: the fur is finally flying! Cancer Cell 2004;5:7-10.
18. Schultz RM, Merriman RL, Andis SL, Bonjouklian R, Grindey GB, Rutherford PG, Gallegos A, Massey K, Powis G. In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res 1995;15:1135-9.
19. Maira SM, Galetic I, Brazil DP, Kaech S, Ingley E, Thelen M, Hemmings BA. Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/AKT and v-AKT at the plasma membrane. Science 2001;294:374-80.
20. Hwang SK, Kwon JT, Park SJ, Chang SH, Lee ES, Chung YS, Beck GR, Jr, Lee KH, Piao L, Park J, Cho MH. Lentivirus-mediated carboxyl-terminal modulator protein gene transfection via aerosol in lungs of K-ras null mice. Gene Ther 2007;14:1721-30.
21. Gammon ST, Villalobos VM, Prior JL, Sharma V, Piwnica-Worms D. Quanitative analysis of permeation peptide complexes labeled with Technetium-99m: chiral and sequence-specific effects on net cell uptake. Bioconjug Chem 2003;14:368-376.
22. Kashiwagi H, McDunn JE, Goedegebuure PS, Gaffney MC, Chang K, Trinkaus K, Piwnica-Worms D, Hotchkiss RS, Hawkins WG. TAT-Bim induces extensive apoptosis in cancer cells. Ann Surg Oncol 2007;6:48.
23. Hotchkiss RS, McConnell KW, Bullok K, Davis CG, Chang KC, Schwulst SJ, Dunne JC, Dietz GP, Bähr M, McDunn JE, Karl IE, Wagner TH, et al. TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocytes apoptosis in vivo. J Immunol 2006;176:5471-77.
24. McConnell KW, Muenzer JT, Chang KC, Davis CG, McDunn JE, Coopersmith CM, Hilliard CA, Hotchkiss RS, Grigsby PW, Hunt CR. Anti-apoptotic peptides protect against radiation-induced cell death. Biochem Biophys Res Commun 2007;355:501-7.
25. Turner TT, Lysiak JJ, Shannon JD, Nguyen QA, Bazemore-Walker CR. Testicular torsion alters the presence of specific proteins in the mouse testis as well as the phosphorylation status of specific proteins. J Androl 2006;27:285-93.
26. Comer JE, Chopra AK, Peterson JW, Köonig R. Direct inhibition of T-Lymphocyte activation by anthrax toxins in vivo. Infect Immun 2005; 73:8275-81.
27. Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits pkb/ akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 2001;7:3269-75.
28. Pham NA, Tsao MS, Cao P, Hedley DW. Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models. Pancreas 2007;35:e16-26.
29. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000;6:2969-72.
30. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play of three Akts. Genes Dev 1999;13:2905-927.
31. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-62.
32. Wang HG, Pathan N, Ethell IM, Krajewski S, Yamaguchi Y, Shibasaki F, McKeon F, Bobo T, Franke TF, Reed JC. Ca2+-induced apoptosis through calcineurin dephosphorylation of Bad. Science 1999; 284:339-43.
33. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multitasking kinase. J Cell Sci 2003;116:1175-86.
34. Ono H, Sakoda H, Fujishiro M, Anai M, Kushiyama A, Fukushima Y, Katagiri H, Ogihara T, Oka Y, Kamata H, Horike N, Uchijima Y, et al. Carboxy-terminal modulator protein induces Akt phosphorylation and activation, thereby enhancing antiapoptotic, glycogen synthetic, and glucose uptake pathways. Am J Physiol Cell Physiol 2007; 293:C1576-85.
35. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV, Cheng JQ. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001;159:431-7.
36. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD, Saji M. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 2001;61:6105-11.
37. Michl P, Downward J. Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z Gastoenterol 2005;43:1133-9.
38. Kleeff J, Reiser C, Hinz U, Bachmann J, Debus J, Jaeger D, Friess H, Büchler MW. Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg 2007;245:566-72.
39. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, Cameron JL, Kern SE, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001;7:3862-8.
40. Argani P, Rosty C, Reiter RE, Wilentz RE, Murugesan SR, Leach SD, Ryu B, Skinner HG, Goggins M, Jaffee EM, Yeo CJ, Cameron JL, et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpresed in pancreatic adenocarcinoma. Cancer Res 2001;61:4320-4.